We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Alliance to Develop Drugs for Heart Disease

By Biotechdaily staff writers
Posted on 08 Jan 2004
A collaboration that could lead to new drugs to treat heart failure and hypertension has been announced by Cytopia (Rensselaer, NY, USA) and Myomatrix Therapeutics (Melbourne, Australia). More...


Myomatrix has worldwide exclusive rights to develop and commercialize therapies for certain cardiovascular diseases by inhibiting a kinase target. The approach has been validated in animal studies and represents a novel mechanism for the treatment of heart failure and hypertension. Cytopia has worldwide exclusive rights to several kinase targets and states that the company has already developed highly potent and specific inhibitors.

"Under the jointly funded work program, Cytopia will provide its specific inhibitors to Myomatrix for testing in animal models, and the data generated will be jointly owned,” said Dr. Kevin Healey, head of Cytopia. "The first product is being targeted at a chronic ‘orphan disease' that has no current treatment and a potential market of U.S.$500 million. The next products will target heart failure and hypertension.”

Cytopia is a drug discovery company focused on the treatment of immune diseases and cancer. Myomatrix is a biopharmaceutical company with core expertise in developing therapies for cardiovascular diseases.

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Prefilled Tubes
Prefilled 5.0ml Tubes
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.